Psychiatry

Family physician Teresa Lovins, MD, highlights key community mental health resources primary care clinicians should know to support patients in crisis.

Family physician Teresa Lovins, MD, explains how primary care clinicians can determine when to manage depression and when urgent referral is needed.

Teresa Lovins, MD, describes the PHQ-9, GAD-7, and other brief screeners that help family physicians identify depression, anxiety, ADHD, and bipolar disorder in everyday practice.

Primary care clinicians see a higher share of visits for depression than mental health professionals largely because they know their patients so well, Lovins said.

Teresa Lovins, MD, highlights a study that showed a 14% increase in rates of safety planning within 2 weeks of a negative screening led to a 25% decrease in attempted suicides.

Teresa Lovins, MD, sees at least 1 or 2 patients a week who have suicidal ideation. Too many of them are at risk for an attempt within a month of those visits.

Mental health issues affect half the population at some point during a lifetime. Teresa Lovins, MD, says FPs are often the first to learn that "something is going on."

One-Day TMS condenses transcranial magnetic stimulation therapy treatment from a daily month-long process to 1 day, with rapid and durable results, NeuroStim says.

The risk for MDD is greatest in the first month after diagnosis and the absolute risk remains elevated even 20 years later, making early detection and treatment imperative.

In the RE104 group receiving the 30-mg dose, clinically meaningful reductions in the primary endpoint were seen on day 1 posttreatment and sustained through day 28 follow-up.

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

The vasopressin V1b antagonist reduced depressive symptoms, with greater effects in genetically-selected patients using a precision psychiatry approach.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The FDA advisory committee overwhelmingly voted against Otsuka's PTSD treatment, citing insufficient evidence from clinical trials for approval.

FDA's Psychopharmacologic Drugs Advisory Committee will evaluate the novel brexpiprazole/sertraline combination, weighing efficacy against existing therapies amid mixed trial results.

Monu Khanna, MD, discusses the benefits of behavioral strategies, including yoga, breathwork, and dancing, in reducing cardiovascular disease risk in patients with obesity.

Maternal depression significantly disrupts parenting behaviors, impacting child development and emotional bonding, according to an updated international literature review.

TSND-201, a rapid-acting neuroplastogen, demonstrated statistically significant symptom improvement by day 10, which was durable throughout the study until Day 64.

A single dose of BPL-003 was associated with improved MADRS scores as early as day 2 that were durable through week 8; phase 3 planning is anticipated.

Authors say their findings support the accumulating evidence that late-life mood disorders may be a prodromal manifestation of dementia vs a risk factor alone.

Your daily dose of the clinical news you may have missed.

ACOG 2025: Joy Baker, MD, discusses the urgent need to prioritize postpartum depression screening, normalize mental health in prenatal care, and strengthen continuity between OB-GYN and primary care.

The novel rapid-acting psychedelic agent produced antidepressant effects within 24 hours after the first infusion, with a -18.5 point change in MADRS from baseline.

Youth depression is often diagnosed during crisis events, underscoring the need for primary care education and enhanced collaborative care resources.